Review

senescence lipid clearance group areg recombinant protein (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems senescence lipid clearance group areg recombinant protein
Senescence Lipid Clearance Group Areg Recombinant Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 51 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+amphiregulin/Recombinant+Mouse+Amphiregulin+Protein/pm41820407-251-30-39
Average 95 stars, based on 51 article reviews

senescence lipid clearance group areg recombinant protein - by Bioz Stars, 2026-09

95/100 stars

Images

Recombinant:

Article Title: The protective roles of integrin α4β7 and Amphiregulin-expressing innate lymphoid cells in lupus nephritis
Article Snippet: .. Recombinant amphiregulin (10 μg; R&D Systems, 989-AR-100/CF) was administered twice weekly for 5 weeks in the IMQ-induced model. ..

Article Title: Investigating the impact of antibiotic-induced dysbiosis on protection from Clostridium difficile colitis by mouse colonic innate lymphoid cells
Article Snippet: .. Mice were administered 10 μg recombinant amphiregulin (R&D systems, catalog #989-AR-100/CF) or PBS through intraperitoneal injections daily for 5 days starting from days −4 of CDI ( ). .. For the IL-33 experiment, mice were injected with 0.75 μg recombinant IL-33 (Biolegend, SanDiego, CA) or PBS for 5 days starting from days −4 of CDI intraperitoneally; this dose has been found to be protective during colitis in previous studies ( , ).

Article Title: Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections
Article Snippet: .. These cells were incubated with recombinant Amphiregulin (R&D) (10 mg/ml). ..

Article Title: The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway
Article Snippet: .. The sources of antibodies and reagents are as followed: anti-pY291 Fas (prepared as previously described and validated for immunoblotting and flow cytometry Fig. ); anti-Src, anti-Yes (R&D Systems); anti-human Fas (C20, for immunoblotting) and anti-Cyclin D1 (Santa Cruz); anti-Fas (Apo1–3, for co-immunoprecipitation) (Enzo); anti-EGFR, anti-pY1068 EGFR, anti-pY705 STAT3, anti-STAT3, anti-pS473 Akt, anti-pT308 Akt, anti-Akt, anti-pErk1/2, and anti-Histone H3 (Cell Signaling Technology); anti-Erk1/2 (Sigma); anti-GAPDH (Calbiochem); horseradish peroxidase conjugated anti-rabbit and anti-mouse (Jackson ImmunoResearch); anti-mouse IgG-Alexa Flour 488 (Life Technology); Recombinant human EGF (Gibco), recombinant amphiregulin (R&D Systems); protein G sepharose beads (Zymed Laboratories); WST-1 (Interchim); Matrigel (BD Bioscience). .. Lipofectamine RNAiMAX reagent (Invitrogen) was used for siRNA transfection according to the manufacturer’s protocol for reverse transfection.

Article Title: Local Group 2 Innate Lymphoid Cells Promote Corneal Regeneration after Epithelial Abrasion.
Article Snippet: .. Administration of Recombinant Amphiregulin Anti-CD90.2 antibodyetreated mice were given 5 mL of recombinant mouse amphiregulin protein (1 mg/mL) (R&D Systems, catalog number 989-AR/CF) ocularly by drop (4 times, one time every 6 hours after corneal wounding). ..

Article Title: Progesterone-Based Therapy Protects Against Influenza by Promoting Lung Repair and Recovery in Females.
Article Snippet: .. Recombinant amphiregulin (10μg; R&D) was administered intraperitoneally every other day using saline as the vehicle. ..

Article Title: Investigating the impact of antibiotic-induced dysbiosis on protection from Clostridium difficile colitis by mouse colonic innate lymphoid cells.
Article Snippet: .. Amphiregulin, IL-33, and anti-amphiregulin treatment Mice were administered 10 μg recombinant amphiregulin (R&D systems, catalog #989-AR-100/CF) or PBS through intraperitoneal injections daily for 5 days starting from days −4 of CDI (27). .. For the IL-33 experiment, mice were injected with 0.75 μg recombinant IL-33 (Biolegend, SanDiego, CA) or PBS for 5 days starting from days −4 of CDI intraperitoneally; this dose has been found to be protective during colitis in previous studies (17, 47).

Mouse Assay:

Incubation:

Western Blot:

Flow Cytometry:

Saline:

Image Search Results

A) For in vivo maturation (yellow box), 4 to 6-week-old female C57Bl/6J mice were stimulated with pregnant mare serum gonadotropin (PMSG) for 46 hours, triggered with human chorionic gonadotropin (hCG) and mature cumulus-oocyte complexes (COCs) were retrieved 14 hours post-trigger. For in vitro culture groups, 4 to 6-week-old female C57Bl/6J mice were stimulated with PMSG and ovaries collected 23 hours later to retrieve immature COCs. For the CAPA treatment group (pink box) COCs were cultured in CAPA pre-medium for 24 hours and then in vitro maturation (IVM) medium containing listed additives for 18 hours. For the standard IVM treatment group (blue box), COCs were cultured in IVM medium for 18 hours. COCs were then used intact for embryology assessments or separated into oocytes and cumulus cells for proteomics and validation experiments. B) For protein assessment in human oocytes, patients underwent a full stimulation protocol for an intracytoplasmic sperm injection (ICSI) cycle as per standard clinical procedures. Following oocyte pickup, immature germinal vesicle (GV) oocytes were collected from the clinic and transported to the lab. Oocytes were allocated into two groups, either fixed at the GV stage, or oocytes underwent rescue-IVM for 24hrs to reach the metaphase II (MII) stage. Immunostaining experiments were performed on both cohorts of oocytes.

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) For in vivo maturation (yellow box), 4 to 6-week-old female C57Bl/6J mice were stimulated with pregnant mare serum gonadotropin (PMSG) for 46 hours, triggered with human chorionic gonadotropin (hCG) and mature cumulus-oocyte complexes (COCs) were retrieved 14 hours post-trigger. For in vitro culture groups, 4 to 6-week-old female C57Bl/6J mice were stimulated with PMSG and ovaries collected 23 hours later to retrieve immature COCs. For the CAPA treatment group (pink box) COCs were cultured in CAPA pre-medium for 24 hours and then in vitro maturation (IVM) medium containing listed additives for 18 hours. For the standard IVM treatment group (blue box), COCs were cultured in IVM medium for 18 hours. COCs were then used intact for embryology assessments or separated into oocytes and cumulus cells for proteomics and validation experiments. B) For protein assessment in human oocytes, patients underwent a full stimulation protocol for an intracytoplasmic sperm injection (ICSI) cycle as per standard clinical procedures. Following oocyte pickup, immature germinal vesicle (GV) oocytes were collected from the clinic and transported to the lab. Oocytes were allocated into two groups, either fixed at the GV stage, or oocytes underwent rescue-IVM for 24hrs to reach the metaphase II (MII) stage. Immunostaining experiments were performed on both cohorts of oocytes.

Article Snippet: Following CAPA pre-IVM, COCs were washed 3 times in CAPA IVM media (bicarbonate-buffered αMEM + 3mg/mL fatty-acid free BSA supplemented with 50 μg/mL gentamycin, 2.5 mIU/mL FSH, 50 ng/mL recombinant mouse amphiregulin (mAREG; catalogue #989-AR, R&D Systems) and 50 ng/mL recombinant epiregulin (mEREG; catalogue #1068-ER, R&D Systems)).

Techniques: In Vivo, In Vitro, Cell Culture, Biomarker Discovery, Injection, Immunostaining

A) Brightfield images of cumulus-oocyte complexes (COCs) following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Red circles mark oocytes, and scale bar is 50 µm. Diagram of in vitro fertilisation (IVF) followed by morphological assessment of embryos at day 2, 5 and 6 of in vitro embryo culture. B) Fertilisation rate (percentage of cleaved embryos per oocyte transferred to culture), D) Day 5 blastocyst rate, F) Day 6 blastocyst rate and G) Day 6 hatching blastocyst rate (percentage of hatching blastocysts per cleaved embryo) following oocyte maturation. Corresponding images of embryos at Day 2 (C), Day 5 (E) and Day 6 (H) are shown. Red arrowheads mark cleaved embryos, red circles show oocytes that failed to cleave, hatched blastocysts (red h), blastocyst (red bl) and fragmented embryos (red f). Images taken at 10x magnification and scale bar denotes 100 µm. All embryo outcome data were arcsine transformed and one-way ANOVA followed by Tukey’s post hoc tests were performed. Numbers above the x axis denote the total number of oocytes (panel B) and total number of cleaved embryos (panel D, F, G) in each oocyte group across the six replicates. Bars with no common superscripts are significantly different (P < 0.05).

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) Brightfield images of cumulus-oocyte complexes (COCs) following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Red circles mark oocytes, and scale bar is 50 µm. Diagram of in vitro fertilisation (IVF) followed by morphological assessment of embryos at day 2, 5 and 6 of in vitro embryo culture. B) Fertilisation rate (percentage of cleaved embryos per oocyte transferred to culture), D) Day 5 blastocyst rate, F) Day 6 blastocyst rate and G) Day 6 hatching blastocyst rate (percentage of hatching blastocysts per cleaved embryo) following oocyte maturation. Corresponding images of embryos at Day 2 (C), Day 5 (E) and Day 6 (H) are shown. Red arrowheads mark cleaved embryos, red circles show oocytes that failed to cleave, hatched blastocysts (red h), blastocyst (red bl) and fragmented embryos (red f). Images taken at 10x magnification and scale bar denotes 100 µm. All embryo outcome data were arcsine transformed and one-way ANOVA followed by Tukey’s post hoc tests were performed. Numbers above the x axis denote the total number of oocytes (panel B) and total number of cleaved embryos (panel D, F, G) in each oocyte group across the six replicates. Bars with no common superscripts are significantly different (P < 0.05).

Techniques: In Vivo, In Vitro, Embryo Culture, Transformation Assay

A) The total number of proteins identified, average number of unique peptides identified/protein and the average protein coverage (%) within oocytes matured in vivo (yellow), following CAPA-IVM (pink) and following standard IVM (blue). B) The total number of proteins identified, average number of unique peptides identified/protein and the average protein coverage (%) within cumulus cells matured in vivo (light yellow), following CAPA-IVM (light pink) and following standard IVM (light blue). Principal component analysis (PCA) from each maturation method ( in vivo (yellow squares), CAPA-IVM (pink circles) and standard IVM (blue diamonds)) for both C) oocytes and D) cumulus cells. E) Venn diagram of shared and unique proteins across the three groups of oocytes. F) Venn diagram of shared and unique proteins across the three groups of cumulus cells.

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) The total number of proteins identified, average number of unique peptides identified/protein and the average protein coverage (%) within oocytes matured in vivo (yellow), following CAPA-IVM (pink) and following standard IVM (blue). B) The total number of proteins identified, average number of unique peptides identified/protein and the average protein coverage (%) within cumulus cells matured in vivo (light yellow), following CAPA-IVM (light pink) and following standard IVM (light blue). Principal component analysis (PCA) from each maturation method ( in vivo (yellow squares), CAPA-IVM (pink circles) and standard IVM (blue diamonds)) for both C) oocytes and D) cumulus cells. E) Venn diagram of shared and unique proteins across the three groups of oocytes. F) Venn diagram of shared and unique proteins across the three groups of cumulus cells.

Techniques: In Vivo

A) Volcano plots showing pairwise comparisons of differential oocyte protein expression in in vivo (yellow), CAPA-IVM (pink) and standard IVM (blue) treatment groups. Coloured dots indicate differentially expressed proteins in each comparison and grey dots indicate proteins below the log2FC ± 1, p-value ≤ 0.05 cutoff. B) All proteins found to be consistently differentially expressed with log2 fold-change and −log10 p- values of CAPA-IVM matured MII oocytes and standard IVM matured MII oocytes compared with in vivo matured MII oocytes (IVO). Bar charts showing the top 20 enriched canonical pathways based on oocyte differential protein expression between C) CAPA- IVM matured MII oocytes and in vivo matured MII oocytes, and D) standard IVM matured MII oocytes and in vivo matured MII oocytes. Shades of green indicate -log10 p value generated from Ingenuity Pathway Analysis software. Scaled proteomic abundances for individual proteins related to biological pathway elevated in E) in vivo oocytes and F) in vitro matured oocytes (n = 4, abundance ratio adjusted p-values and mean ± standard deviation).

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) Volcano plots showing pairwise comparisons of differential oocyte protein expression in in vivo (yellow), CAPA-IVM (pink) and standard IVM (blue) treatment groups. Coloured dots indicate differentially expressed proteins in each comparison and grey dots indicate proteins below the log2FC ± 1, p-value ≤ 0.05 cutoff. B) All proteins found to be consistently differentially expressed with log2 fold-change and −log10 p- values of CAPA-IVM matured MII oocytes and standard IVM matured MII oocytes compared with in vivo matured MII oocytes (IVO). Bar charts showing the top 20 enriched canonical pathways based on oocyte differential protein expression between C) CAPA- IVM matured MII oocytes and in vivo matured MII oocytes, and D) standard IVM matured MII oocytes and in vivo matured MII oocytes. Shades of green indicate -log10 p value generated from Ingenuity Pathway Analysis software. Scaled proteomic abundances for individual proteins related to biological pathway elevated in E) in vivo oocytes and F) in vitro matured oocytes (n = 4, abundance ratio adjusted p-values and mean ± standard deviation).

Techniques: Expressing, In Vivo, Comparison, Generated, Software, In Vitro, Standard Deviation

A) Eukaryotic initiation factor 2A (EIF2A, magenta), B) ribosomal protein L24 (RPL24, magenta) and C) clathrin light chain B (CLTB, magenta) immunocytochemistry in MII oocytes following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Nuclei were counterstained with Hoechst (blue). Images taken at 40x magnification and scale bar denotes 25 µm. Fluorescence intensity of (D) EIF2A, (E) RPL24 and (F) CLTB was quantified in oocytes from MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Integrated density values were taken from individual COCs and normalised to the in vivo control mean intensity of each biological replicate (dots). Data are presented as the mean of three replicates ± SEM. Statistical analyses were performed using one-way ANOVA followed by Tukey’s post hoc tests. Bars with no common superscripts are significantly different (P < 0.05). A.U, arbitrary units. G) Immunofluorescent staining for translation machinery (RPL24 and EIF2A) and endocytosis (CLTB) in human prophase I (GV) and metaphase II oocytes. Nuclei were counterstained with Hoechst (blue). Images taken at 40x magnification and scale bar denotes 50 µm.

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) Eukaryotic initiation factor 2A (EIF2A, magenta), B) ribosomal protein L24 (RPL24, magenta) and C) clathrin light chain B (CLTB, magenta) immunocytochemistry in MII oocytes following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Nuclei were counterstained with Hoechst (blue). Images taken at 40x magnification and scale bar denotes 25 µm. Fluorescence intensity of (D) EIF2A, (E) RPL24 and (F) CLTB was quantified in oocytes from MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Integrated density values were taken from individual COCs and normalised to the in vivo control mean intensity of each biological replicate (dots). Data are presented as the mean of three replicates ± SEM. Statistical analyses were performed using one-way ANOVA followed by Tukey’s post hoc tests. Bars with no common superscripts are significantly different (P < 0.05). A.U, arbitrary units. G) Immunofluorescent staining for translation machinery (RPL24 and EIF2A) and endocytosis (CLTB) in human prophase I (GV) and metaphase II oocytes. Nuclei were counterstained with Hoechst (blue). Images taken at 40x magnification and scale bar denotes 50 µm.

Techniques: Immunocytochemistry, In Vivo, Fluorescence, Control, Staining

A) Volcano plots showing pairwise comparisons of differential cumulus cell protein expression in in vivo (yellow), CAPA-IVM (pink) and IVM (blue) treatment groups. Coloured dots indicate differentially expressed proteins in each comparison and grey dots indicate proteins below the log2FC ± 1, p-value ≤ 0.05 cutoff. B) All proteins found to be consistently differentially expressed with log2 fold-change and −log10 p-values of cumulus cells from CAPA-IVM and IVM maturation groups, compared with in vivo matured cumulus cells (IVO).

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) Volcano plots showing pairwise comparisons of differential cumulus cell protein expression in in vivo (yellow), CAPA-IVM (pink) and IVM (blue) treatment groups. Coloured dots indicate differentially expressed proteins in each comparison and grey dots indicate proteins below the log2FC ± 1, p-value ≤ 0.05 cutoff. B) All proteins found to be consistently differentially expressed with log2 fold-change and −log10 p-values of cumulus cells from CAPA-IVM and IVM maturation groups, compared with in vivo matured cumulus cells (IVO).

Techniques: Expressing, In Vivo, Comparison

Bar charts showing the top 20 enriched canonical pathways based on cumulus cell differential protein expression between A) CAPA-IVM matured MII COCs and in vivo matured MII COCs, and B) IVM matured MII COCs and in vivo matured MII COCs. Shades of green indicate -log10 p value generated from Ingenuity Pathway Analysis software. Scaled proteomic abundances for individual proteins related to biological pathway elevated in C) in vivo cumulus cells and D) in vitro matured cumulus cells (n = 4, abundance ratio adjusted p-values and mean ± standard deviation).

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: Bar charts showing the top 20 enriched canonical pathways based on cumulus cell differential protein expression between A) CAPA-IVM matured MII COCs and in vivo matured MII COCs, and B) IVM matured MII COCs and in vivo matured MII COCs. Shades of green indicate -log10 p value generated from Ingenuity Pathway Analysis software. Scaled proteomic abundances for individual proteins related to biological pathway elevated in C) in vivo cumulus cells and D) in vitro matured cumulus cells (n = 4, abundance ratio adjusted p-values and mean ± standard deviation).

Techniques: Expressing, In Vivo, Generated, Software, In Vitro, Standard Deviation

A) Ferredoxin 1 (FDX1, magenta) and C) D-3-phosphoglycerate dehydrogenase (PHGDH, magenta) immunocytochemistry colocalised with phalloidin (green) in MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Nuclei were counterstained with Hoechst (blue). First column shows intact cumulus oocyte complexes, with the subsequent columns showing representative images of cumulus cells. Images taken at 40x magnification and scale bar denotes 50 µm. Fluorescence intensity of (B) FDX1 and (D) PHGDH was quantified in cumulus cells from MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Integrated density values were taken from individual COCs and normalised to the in vivo control mean intensity of each biological replicate (dots). Data are presented as the mean of three replicates ± SEM. Statistical analyses were performed using one-way ANOVA followed by Tukey’s post hoc tests. Bars with no common superscripts are significantly different (P < 0.05). A.U, arbitrary units.

Journal: bioRxiv

Article Title: A proteomic signature of oocyte quality from models of varying oocyte developmental competence

doi: 10.64898/2026.01.20.700687

Figure Lengend Snippet: A) Ferredoxin 1 (FDX1, magenta) and C) D-3-phosphoglycerate dehydrogenase (PHGDH, magenta) immunocytochemistry colocalised with phalloidin (green) in MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Nuclei were counterstained with Hoechst (blue). First column shows intact cumulus oocyte complexes, with the subsequent columns showing representative images of cumulus cells. Images taken at 40x magnification and scale bar denotes 50 µm. Fluorescence intensity of (B) FDX1 and (D) PHGDH was quantified in cumulus cells from MII COCs following in vivo maturation (yellow), CAPA IVM (pink) and standard IVM (IVM; blue). Integrated density values were taken from individual COCs and normalised to the in vivo control mean intensity of each biological replicate (dots). Data are presented as the mean of three replicates ± SEM. Statistical analyses were performed using one-way ANOVA followed by Tukey’s post hoc tests. Bars with no common superscripts are significantly different (P < 0.05). A.U, arbitrary units.

Techniques: Immunocytochemistry, In Vivo, Fluorescence, Control

Review

senescence lipid clearance group areg recombinant protein (R&D Systems)

Structured Review

Images

Related Articles

Recombinant:

Mouse Assay:

Incubation:

Western Blot:

Flow Cytometry:

Saline:

Similar Products

Image Search Results